Literature DB >> 21880026

Hepatocellular carcinoma and vitamin D: a review.

Kun-Chun Chiang1, Chun-Nan Yeh, Miin-Fu Chen, Tai C Chen.   

Abstract

The non-classical actions of vitamin D, namely antiproliferation, pro-differentiation, pro-apoptosis, anti-inflammation, and immune regulation, have received great attention during the past decade. Increasing evidence from epidemiological studies showing the inverse association between vitamin D status and incidence of many forms of cancer as well as biochemical studies has suggested that vitamin D deficiency may play a role in the cause and progression of these types of cancer. Recently, vitamin D and its analogs have been deemed as potential regimen to treat a variety of cancers alone or in combination with other drugs. Although, the epidemiologic evidence regarding the association of vitamin D and hepatocellular carcinoma (HCC) is still inconclusive, biochemical evidence clearly indicates that HCC cells are responsive to the inhibitory effect of vitamin D and its analogs. In this review, we discuss the current status of HCC and its treatment, the source, metabolism, functions, and the mechanism of actions of vitamin D, and the biochemical studies of vitamin D analogs and their implications in the prevention and treatment of HCC.
© 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21880026     DOI: 10.1111/j.1440-1746.2011.06892.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  29 in total

Review 1.  Nutrition and Hepatocellular Cancer.

Authors:  Kerstin Schütte; Christian Schulz; Peter Malfertheiner
Journal:  Gastrointest Tumors       Date:  2015-11-18

2.  Effects of vitamin D3 stimulation of thioredoxin-interacting protein in hepatocellular carcinoma.

Authors:  James P Hamilton; James J Potter; Lahari Koganti; Stephen J Meltzer; Esteban Mezey
Journal:  Hepatol Res       Date:  2014-03-25       Impact factor: 4.288

3.  Evaluation of the potential therapeutic role of a new generation of vitamin D analog, MART-10, in human pancreatic cancer cells in vitro and in vivo.

Authors:  Kun-Chun Chiang; Chun-Nan Yeh; Jun-Te Hsu; Ta-sen Yeh; Yi-yin Jan; Chun-Te Wu; Huang-Yang Chen; Shyh-Chuan Jwo; Masashi Takano; Atsushi Kittaka; Horng-Heng Juang; Tai C Chen
Journal:  Cell Cycle       Date:  2013-04-02       Impact factor: 4.534

4.  Therapeutic Efficacy of Vitamin D in Experimental c-MET-β-Catenin-Driven Hepatocellular Cancer.

Authors:  Akiko Matsuda; Kaori Ishiguro; Irene K Yan; Tushar Patel
Journal:  Gene Expr       Date:  2018-08-29

Review 5.  Vitamin D receptor signaling and pancreatic cancer cell EMT.

Authors:  Zhiwei Li; Junli Guo; Keping Xie; Shaojiang Zheng
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 6.  New prognostic markers in liver cirrhosis.

Authors:  Vincent Di Martino; Delphine Weil; Jean-Paul Cervoni; Thierry Thevenot
Journal:  World J Hepatol       Date:  2015-05-28

7.  Association of 25-Hydroxyvitamin D with Liver Cancer Incidence and Chronic Liver Disease Mortality in Finnish Male Smokers of the ATBC Study.

Authors:  Gabriel Y Lai; Jian-Bing Wang; Stephanie J Weinstein; Dominick Parisi; Ronald L Horst; Katherine A McGlynn; Satu Männistö; Demetrius Albanes; Neal D Freedman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-05-02       Impact factor: 4.254

Review 8.  Potent 19-norvitamin D analogs for prostate and liver cancer therapy.

Authors:  Atsushi Kittaka; Akihiro Yoshida; Kun-Chun Chiang; Masashi Takano; Daisuke Sawada; Toshiyuki Sakaki; Tai C Chen
Journal:  Future Med Chem       Date:  2012-10       Impact factor: 3.808

9.  Single-nucleotide polymorphism at CYP27B1-1260, but not VDR Taq I, is possibly associated with persistent hepatitis B virus infection.

Authors:  Qianqian Zhu; Na Li; Qunying Han; Zhu Li; Guoyu Zhang; Fang Li; Pingping Zhang; Jinghong Chen; Yi Lv; Zhengwen Liu
Journal:  Genet Test Mol Biomarkers       Date:  2012-09

Review 10.  Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer.

Authors:  Abigale Lade; Luke A Noon; Scott L Friedman
Journal:  Curr Opin Oncol       Date:  2014-01       Impact factor: 3.645

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.